Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies.

Cancer medicine - 1 Nov 2022

Chen Shuchen, Zhu Honglin, Jin Meizi, Yuan Hongling, Liu Zhenzhen, Li Jielin, Zhang Xiang, Meng Lihui, Li Ting, Diao Yuzhu, Gao Hong, Hong Chengyu, Zhu Xinjiang, Zheng Jian, Li Fei, Niu Yanling, Ma Tonghui, Li Xiaoling

Abstract excerpt

BACKGROUND: Isocitrate dehydrogenase (IDH) is an appealing target for anticancer therapy, and IDH (IDH1/2) inhibitors have been approved for targeted therapy of acute myeloid leukemia (AML) and Cholangiocarcinoma. The therapeutic potential of IDH inhibitors for non-small-cell lung cancer (NSCLC) patients is under active clinical investigation. Thus, it would be necessary and meaningful to study the molecular and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to China

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35526267
DOI: 10.1002/cam4.4764
PMCID: PMC9678110

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies.PMID 35526267Read ↗

Landscape of IDH1/2 mutations in Chinese patients with solid tumors: A pan-cancer analysis.Semantic proximity Read ↗

Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations.Semantic proximity Read ↗

IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.Semantic proximity Read ↗

Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.Semantic proximity Read ↗

Efficacy and safety of IDH inhibitors in IDH-mutated cancers: a systematic review and meta-analysis of 4 randomized controlled trials.Semantic proximity Read ↗

A new functional IDH2 genetic variant is associated with the risk of lung cancer.Semantic proximity Read ↗

Association of IDH1 mutations with survival and recurrence in resected intrahepatic cholangiocarcinoma received or not received adjuvant chemotherapy.Semantic proximity Read ↗

Genetic variants in genes of tricarboxylic acid cycle key enzymes are associated with prognosis of patients with non-small cell lung cancer.Semantic proximity Read ↗

Determination of Isocitrate Dehydrogenase (IDH1) mutation in laryngeal squamous cell carcinoma specimensSemantic proximity Read ↗

Analysis of gene mutation spectrum and prevention and treatment of lung cancer patients in Qujing, Yunnan Province, ChinaSemantic proximity Read ↗

IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype.Semantic proximity Read ↗

Unique characteristics of G719X and S768I compound double mutations of epidermal growth factor receptor (EGFR) gene in lung cancer of coal-producing areas of East Yunnan in Southwestern ChinaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.